Oxea, a global supplier of Oxo Intermediates and Oxo Derivatives, today announced for the fourth quarter of 2012 a strong earnings increase compared with the fourth quarter of 2011.
Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International